Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Status:
Terminated
Trial end date:
2019-03-14
Target enrollment:
Participant gender:
Summary
This phase 1 study was developed to identify recommended phase 2 doses (RP2Ds) of AR-42 and
pazopanib when given in combination for subsequent clinical trials and may have potentially
identified candidate pharmacodynamic and predictive biomarkers.